A randomized controlled study of ciprofol (HSK3486) and propofol for short urological operations in elderly patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600116551

Enrollment

Unknown

Registered

2026-01-12

Start date

2026-01-17

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urology in elderly patients

Interventions

Experimental group:Anesthesia induction: Propofol 0.3 mg/kg, Remifentanil 1 µg/kg

Anesthesia maintenance: Propofol 0.3–1.8 mg/kg·h, Remifentanil 0.05–0.2 µg/kg·min

Control group:Anesthesia induction: Propofol 1.5 mg/kg, Remifentanil 1 µg/kg. Anesthesia maintenance: Propofol 1.5-9 mg/kg·h, Remifentanil 0.05-0.2 µg/kg·min

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 65 years or older who are scheduled for elective urological surgery (including ureteroscopic ureteral stent removal, replacement, laser lithotripsy, stone extraction, etc., with an average surgery time of less than 3 hours); 2. American Society of Anesthesiologists (ASA) classification I-III; 3. Patients have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Difficult airway (modified Mallampati score of III or IV) or pre-existing abnormal medication behavior; 2. Recent upper respiratory tract infection or other pathological changes in the throat; 3. Suspected allergy or contraindication to cyclopropane, propofol, or medications specified in this study (sufentanil citrate, remifentanil hydrochloride, dexmedetomidine, atropine sulfate); 4. Severe neurological, respiratory, or cardiovascular diseases; abuse or long-term use of anesthetics, sedatives, or analgesics; 5. Urological surgery requiring high muscle relaxation or deemed unsuitable by the investigator, or those who refuse to participate in this clinical trial.

Design outcomes

Primary

Measure	Time frame
Success rate of anesthesia induction;The success rate of inhibiting laryngeal mask reaction;	—

Secondary

Measure	Time frame
Quality of anesthesia recovery;Perioperative adverse events;	—

Countries

China

Contacts

Public ContactZheng Mingzhi

Zhuzhou Central Hospital (Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Central South University)

zhengmingzhi@csu.edu.cn+86 138 7419 5026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026